Lauren M Ellman1, Shannon K Murphy2, Seth D Maxwell3, Evan M Calvo4, Thomas Cooper5, Catherine A Schaefer6, Michaeline A Bresnahan7, Ezra S Susser8, Alan S Brown9. 1. Department of Psychology, Temple University, Weiss Hall, 1701 N. 13(th) Street, Philadelphia, PA 19106, United States of America. Electronic address: ellman@temple.edu. 2. Department of Psychology, Temple University, Weiss Hall, 1701 N. 13(th) Street, Philadelphia, PA 19106, United States of America. Electronic address: Shannon.k.murphy@temple.edu. 3. Department of Psychology, Temple University, Weiss Hall, 1701 N. 13(th) Street, Philadelphia, PA 19106, United States of America. Electronic address: seth.maxwell@temple.edu. 4. Department of Psychology, Temple University, Weiss Hall, 1701 N. 13(th) Street, Philadelphia, PA 19106, United States of America. Electronic address: evancalvo@temple.edu. 5. Analytic Psychopharmacology, Nathan S. Kline Institute, 140 Old Orangeburg Road Orangeburg, NY 10962, United States of America; New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY 10032, United States of America; Department of Psychiatry, Columbia University, 1051 Riverside Drive, New York, NY 10032, United States of America. Electronic address: Tom.Cooper@nki.rfmh.org. 6. Division of Research, Kaiser Permanente, 2000 Broadway, Oakland, CA 94612, United States of America. Electronic address: cathy.schaefer@kp.org. 7. Department of Epidemiology, Columbia University Mailman School of Public Health, 722 West 168(th) Street, New York, NY 10032, United States of America; New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY 10032, United States of America. Electronic address: mab29@columbia.edu. 8. Department of Epidemiology, Columbia University Mailman School of Public Health, 722 West 168(th) Street, New York, NY 10032, United States of America; New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY 10032, United States of America. Electronic address: ess8@cumc.columbia.edu. 9. Department of Epidemiology, Columbia University Mailman School of Public Health, 722 West 168(th) Street, New York, NY 10032, United States of America; New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY 10032, United States of America; Department of Psychiatry, Columbia University, 1051 Riverside Drive, New York, NY 10032, United States of America. Electronic address: asb11@columbia.edu.
Abstract
INTRODUCTION: Maternal stress during pregnancy has been repeatedly linked to increased risk for schizophrenia; however, no study has examined maternal cortisol during pregnancy and risk for the disorder. Study aims were to determine whether prenatal cortisol was associated with risk for schizophrenia and risk for an intermediate phenotype-decreased fetal growth-previously linked to prenatal cortisol and schizophrenia. Timing of exposure and fetal sex also were examined given previous findings. METHODS: Participants were 64 cases diagnosed with schizophrenia spectrum disorders (SSD) and 117 controls from a prospective birth cohort study. Maternal cortisol was determined from stored sera from each trimester and psychiatric diagnoses were assessed from offspring using semi-structured interviews and medical records review. RESULTS: Maternal cortisol during pregnancy was not associated with risk for offspring schizophrenia. There was a significant interaction between 3rd trimester cortisol and case status on fetal growth. Specifically, cases exposed to higher 3rd trimester maternal cortisol had significantly decreased fetal growth compared to controls. In addition, these findings were restricted to male offspring. CONCLUSIONS: Our results indicate that higher prenatal cortisol is associated with an intermediate phenotype linked to schizophrenia, fetal growth, but only among male offspring who developed schizophrenia. Findings were consistent with evidence that schizophrenia genes may disrupt placental functioning specifically for male fetuses, as well as findings that males are more vulnerable to maternal cortisol during pregnancy. Finally, results suggest that examining fetal sex and intermediate phenotypes may be important in understanding the mechanisms involved in prenatal contributors to schizophrenia.
INTRODUCTION: Maternal stress during pregnancy has been repeatedly linked to increased risk for schizophrenia; however, no study has examined maternal cortisol during pregnancy and risk for the disorder. Study aims were to determine whether prenatal cortisol was associated with risk for schizophrenia and risk for an intermediate phenotype-decreased fetal growth-previously linked to prenatal cortisol and schizophrenia. Timing of exposure and fetal sex also were examined given previous findings. METHODS:Participants were 64 cases diagnosed with schizophrenia spectrum disorders (SSD) and 117 controls from a prospective birth cohort study. Maternal cortisol was determined from stored sera from each trimester and psychiatric diagnoses were assessed from offspring using semi-structured interviews and medical records review. RESULTS: Maternal cortisol during pregnancy was not associated with risk for offspring schizophrenia. There was a significant interaction between 3rd trimester cortisol and case status on fetal growth. Specifically, cases exposed to higher 3rd trimester maternal cortisol had significantly decreased fetal growth compared to controls. In addition, these findings were restricted to male offspring. CONCLUSIONS: Our results indicate that higher prenatal cortisol is associated with an intermediate phenotype linked to schizophrenia, fetal growth, but only among male offspring who developed schizophrenia. Findings were consistent with evidence that schizophrenia genes may disrupt placental functioning specifically for male fetuses, as well as findings that males are more vulnerable to maternal cortisol during pregnancy. Finally, results suggest that examining fetal sex and intermediate phenotypes may be important in understanding the mechanisms involved in prenatal contributors to schizophrenia.
Authors: Laura R Stroud; Catherine Solomon; Edmond Shenassa; George Papandonatos; Raymond Niaura; Lewis P Lipsitt; Kaja Lewinn; Stephen L Buka Journal: Psychoneuroendocrinology Date: 2007-01-31 Impact factor: 4.905
Authors: M G Eide; D Moster; L M Irgens; T Reichborn-Kjennerud; C Stoltenberg; R Skjærven; E Susser; K Abel Journal: Psychol Med Date: 2013-01-09 Impact factor: 7.723
Authors: Curt A Sandman; Megan M Curran; Elysia Poggi Davis; Laura M Glynn; Kevin Head; Tallie Z Baram Journal: Am J Psychiatry Date: 2018-03-02 Impact factor: 18.112
Authors: Miranda Bridgwater; Peter Bachman; Brenden Tervo-Clemmens; Gretchen Haas; Rebecca Hayes; Beatriz Luna; Dean F Salisbury; Maria Jalbrzikowski Journal: Psychol Med Date: 2020-10-06 Impact factor: 10.592
Authors: Aroa Mañas-Ojeda; Francisco Ros-Bernal; Francisco E Olucha-Bordonau; Esther Castillo-Gómez Journal: Int J Mol Sci Date: 2020-08-13 Impact factor: 5.923
Authors: Marta Perez-Rando; Hector Carceller; Esther Castillo-Gomez; Clara Bueno-Fernandez; Clara García-Mompó; Javier Gilabert-Juan; Ramón Guirado; Ana Paula Pesarico; Juan Nacher Journal: Neurobiol Stress Date: 2022-05-13